The new reduced-form NAD+ precursor: what it is, what the data say, and what to watch out for.
TL;DR: NMNH is the reduced form of NMN and looks more potent than NMN in cells and mice, but human evidence is still early. A completed industry-sponsored trial in 80 adults (NCT06889740) evaluated safety and pharmacokinetics; full published results are pending. If you want to experiment, choose a transparent product and keep expectations realistic: lab potency does not guarantee real-world benefits.
NMNH (dihydronicotinamide mononucleotide) is a reduced form of nicotinamide mononucleotide. In the NAD+ biosynthetic pathway, NMN is normally converted into NAD+ by NMNAT enzymes. NMNH appears to bypass some rate-limiting steps more efficiently, producing larger and faster rises in intracellular NAD+ in preclinical models.
The compound first drew serious attention after a 2021 study in the FASEB Journal reported that NMNH was a "new and potent NAD+ precursor in mammalian cells and mice." Researchers found that NMNH raised NAD+ more effectively than NMN in several cell lines and increased liver NAD+ when given orally to mice.
Zapata-Pérez and colleagues showed that:
This was enough to make NMNH the most-talked-about next-generation NAD+ precursor. However, the study did not measure lifespan, disease endpoints or long-term safety in animals, and no human data were included.
Bottom line: NMNH is a genuine scientific advance in NAD+ precursor chemistry, but it is not yet a proven human longevity intervention.
Human NMNH research is growing but still limited:
A 2026 review in Nature Metabolism of NAD+ precursor supplementation in human ageing concluded that evidence for meaningful clinical benefits in healthy adults remains mixed across all precursors, not just NMNH.
500mg NMNH per serving | 60 capsules | Amazon UK
★★★★★ 4.5/5 from Amazon UK reviews
Read full review →Welzo's NMNH product is one of the few UK-listed options that clearly discloses a 500mg dose of reduced-form NMNH per capsule. It is marketed as an "Advanced NAD+ Formula" and sold via Amazon UK.
Why it stands out:
Caveats:
Most NMNH supplements, including Welzo's, provide 500mg per capsule. Because human dose-response data are sparse, the safest approach is to follow the label and not exceed one serving per day. Take with food if you experience nausea or stomach upset.
Do not stack NMNH with other NAD+ precursors (NMN, NR, niacin) unless you have calculated total intake and consulted a clinician. There is no evidence that combining precursors adds benefit, and it increases the risk of side effects.
| Feature | NMNH | NMN | NR |
|---|---|---|---|
| Form | Reduced NMN | Standard nucleotide | Nucleoside |
| Preclinical NAD+ potency | Strongest | Strong | Moderate |
| Human trial volume | Small | Moderate | Larger |
| Long-term safety data | Limited | Short-term only | Moderate |
| UK availability | Growing | Wide | Wide |
For UK buyers, the choice should be driven by risk tolerance and curiosity, not by certainty. NMNH is the newest and least-tested option. NMN and NR have more human data but are still not proven longevity interventions.
"Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice." Key preclinical study.
View DOICompleted 80-participant randomised trial evaluating safety, tolerability and pharmacokinetics of NMNH in healthy adults.
View ClinicalTrials.govReview of human NAD+ precursor supplementation, noting mixed clinical evidence and the need for longer trials.
View ArticleNMNH stands for dihydronicotinamide mononucleotide, the reduced form of NMN. In preclinical models it is converted into NAD+ more efficiently than standard NMN, raising cellular NAD+ levels more potently. Human data are still emerging.
NMNH is more potent than NMN in cell and mouse studies, but human outcome data are limited. It is not proven to be better for healthy adults in real-world use.
Human dose-response data for NMNH are sparse. Products such as Welzo NMNH provide 500mg per serving. Do not exceed the label dose and speak to a clinician if you have medical conditions.
Yes. EffePharm's UthPeak NMNH trial (NCT06889740) was completed with 80 healthy adults, evaluating safety, tolerability and pharmacokinetics. Full peer-reviewed results are pending.
This article contains affiliate links, including a link to Welzo NMNH on Amazon UK. LongevityTortoise may earn a small commission if you purchase through these links, at no extra cost to you. This does not influence our editorial judgements.